-Author name in bold denotes the presenting author
-Asterisk * with author name denotes a Non-ASH member
Clinically Relevant Abstract denotes an abstract that is clinically relevant.

PhD Trainee denotes that this is a recommended PHD Trainee Session.

Ticketed Session denotes that this is a ticketed session.

3375 Study Assessing the All4Cure Health Technology Intervention on Patient Activation in Multiple Myeloma

Program: Oral and Poster Abstracts
Session: 652. Multiple Myeloma: Clinical and Epidemiological: Poster II
Hematology Disease Topics & Pathways:
Research, Clinical Research, emerging technologies, Technology and Procedures, Study Population, Human
Sunday, December 10, 2023, 6:00 PM-8:00 PM

Mehdi M. Moezi, MD1, Mohamad Kanaan, MD2*, Patrick M. Travis3*, Tara Graff4*, Cheng Zheng5*, Jessa Dunivan5*, Tiffany Wood, BS6*, Sophia Essiet6*, Jessica Faucheaux6*, Brian Decker7*, Jennifer Wren5*, Leena Chhun5*, Jayne Piboonvaranggoon5*, Mark Walker, Phd8*, Trudy Buckingham9*, Joseph Guidi10*, Shannon Altimari11* and C. Anthony Blau, MD5*

1Cancer Specialists of North Florida, Fleming Island Cancer Center, Fleming Island, FL
2Northwest Medical Specialties, Puyallup, WA
3Highlands Oncology Group, Rogers, AR
4Mission Cancer and Blood, Des Moines, IA
5All4Cure, Seattle, WA
6Exigent Research, Tacoma, WA
7Electronic Medical Office Logistics (EMOL Health), Royal Oak, MI
8Walker Research Consulting, Germantown, TN
9GSK, Durham, NC
10GSK, Collegeville, PA
11GSK, Baar, Switzerland


Over the past 2 decades, outcomes have improved markedly in patients with multiple myeloma, a result attributable to the development of highly effective agents such as immunomodulators, proteasome inhibitors, and anti-CD38 monoclonal antibodies. However, multiple myeloma remains incurable despite these advances. Furthermore, with each successive relapse, the disease becomes increasingly resistant to treatment. Therefore, patients need methods to best identify those regimens most likely to benefit them.

All4Cure has built a myeloma-focused knowledge-sharing platform for patients, clinicians, and researchers. Patients register and sign HIPAA (Health Insurance Portability and Accountability Act) release forms allowing All4Cure to access all medical records from all institutions from which they have received care. A team of myeloma-dedicated medical data specialists then extracts information from the medical records and displays it on each patient’s deidentified, personalized dashboard. Patient dashboards display results of monthly patient-reported outcome (PRO) surveys and feature a graph depicting all treatments and responses, from diagnosis to present. A summary is also provided, containing a narrative of the patient’s relevant past medical history. This allows a community of >2000 participating patients, clinicians, and researchers to post comments, questions, or suggestions in a discussion panel. With >800 participating patients with multiple myeloma, All4Cure can help inform the treatment decisions of a patient and their oncologist by providing insight into the treatment choices and outcomes of hundreds of other patients.

Patient activation levels predict a broad range of health-related behaviors and outcomes and can be assessed using the 13-item Patient Activation Measure (PAM-13) instrument. Here we report an ongoing prospective cohort study to evaluate the impact of All4Cure enrollment on patient activation levels.


The trial is enrolling 200 adults aged ≥18 years with a diagnosis of multiple myeloma. Patients unable to engage with the platform or who have previously enrolled in All4Cure are excluded. After providing informed consent, patients will complete quarterly PAM-13 surveys, monthly PRO assessments, and surveys to assess their attitudes regarding All4Cure at baseline and on completion of the 12-month study. Oncologists also consent to answer surveys to assess their attitudes regarding All4Cure at baseline and on study completion.

The primary objective of the trial is to assess the effect of All4Cure enrollment on patient activation as assessed using PAM-13. Secondary objectives include evaluation of the associations between patient activation and symptom burden and patient and physician expectations of the utility of the platform. The trial is registered at ClinicalTrials.gov (NCT05673083) and sponsored by the GSK Patient Empowerment Alliance, a program created to help test, measure, and validate tools that show potential to empower patients as core members of their oncology care team, with the goal of improving care outcomes.

Disclosures: Kanaan: Tempus: Consultancy; Northwest Medical Specialties: Current Employment, Current holder of stock options in a privately-held company. Graff: Kite: Consultancy, Honoraria; Lilly: Consultancy, Honoraria; ADC Therapeutics: Consultancy, Honoraria; AbbVie: Consultancy, Honoraria; Gilead: Consultancy, Honoraria; BMS: Consultancy, Honoraria; Beigene: Consultancy, Honoraria; Genentech: Consultancy, Honoraria; Genmab: Consultancy, Honoraria. Zheng: JNJ: Current holder of stock options in a privately-held company; PFE: Current holder of stock options in a privately-held company; All4Cure: Current Employment. Dunivan: All4Cure: Current Employment, Research Funding; Northwest Medical Specialties, PLL: Ended employment in the past 24 months; Infervision: Consultancy; Canopy Care: Consultancy. Wood: Quality Cancer Care Alliance, LLC.: Current Employment; xigent Research Network, LLC.: Current Employment. Faucheaux: Pontchartrain Cancer Center: Consultancy; Exigent Research: Current Employment. Decker: All4Cure: Current holder of stock options in a privately-held company. Wren: All4Cure: Current Employment, Current holder of stock options in a privately-held company. Chhun: All4Cure: Current Employment. Piboonvaranggoon: All4Cure: Current Employment. Buckingham: Gilead: Current Employment; GSK: Ended employment in the past 24 months. Guidi: GSK: Current Employment. Altimari: GSK: Current Employment. Blau: All4Cure: Consultancy, Current holder of stock options in a privately-held company.

*signifies non-member of ASH